DeCure for Epidermolysis bullosa simplex 1C, localized
DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for epidermolysis bullosa simplex 1C, localized — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEpidermolysis bullosa simplex 1C, localized maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for epidermolysis bullosa simplex 1c, localized is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
galactokinase 1 (GALK1) — GALK1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet adpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7RCM · 2.1 Å · ligand ADENOSINE-5'-DIPHOSPHATE (ADP). Experimental structure, not a prediction.
What the evidence adds up to
In a 2010 review, inherited epidermolysis bullosa was described as caused by mutations in at least 14 genes, with a revised classification system identifying new phenotypes, genotypes, and modes of transmission. At that time, clinical trials were being pursued to test gene replacement therapy, stem cell transplantation, and treatment with injected allogeneic fibroblasts or recombinant type VII collagen in humans. No specific results from those trials were reported in the abstract.
A 2020 description states that epidermolysis bullosa simplex (EBS), the most common type, is dominantly inherited and that treatment remains a major challenge. The abstract gives no numbers on survival or response rates, and no drug is mentioned.
A 2025 abstract (published in Slovenian) notes that at least 20 different genes are now implicated, with four basic disease types — simplex, junctional, dystrophic, and Kindler syndrome — and at least 30 clinically distinct subtypes. It mentions complications in skin, mucous membranes, or other organs in severe forms, but again provides no trial data, no drug names, and no quantitative outcomes.
For epidermolysis bullosa simplex 1C, localized, no abstract in this set reports any clinical trial result, any drug tested, or any measured improvement in blistering or quality of life. What is still missing are completed, published trials with patient-level outcomes for this specific subtype, adequate funding for stratified studies that separate localized from severe forms, and trial designs that can detect meaningful change in a slowly progressive, localised disease.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Pediatrics · 2010 · 54 citations
Inherited epidermolysis bullosa: recent basic and clinical advances
AbstractPURPOSE OF REVIEW: This review highlights key findings, both clinical and basic, that have been published in the field of inherited epidermolysis bullosa within the past few years. RECENT FINDINGS: New epidermolysis bullosa phenotypes, genotypes and modes of transmission have been identified, resulting in a revised classification system. Detailed evidence-based data are now available on the risk of extracutaneous complications in each of the major epidermolysis bullosa subtypes. Studies are now underway to try to better explain the biological aggressiveness of squamous cell carcinomas arising in epidermolysis bullosa skin. Cell and animal models have been refined and used to ascertain the feasibility of gene replacement therapy, stem cell transplantation, and treatment with injected allogeneic fibroblasts or recombinant type VII collagen. As a result, clinical trials are now being pursued to test each of these in humans. SUMMARY: Epidermolysis bullosa is caused by mutations in at least 14 genes, leading to a broad spectrum of entities, each of which has its own relative risk for the development of specific extracutaneous complications and/or premature death. Intensive research, both basic and clinical, is bringing us closer to more effective treatments and possibly even a cure.
Slovenska pediatrija revija pediatrov Slovenije in specialistov šolske ter visokošolske medicine Slovenije · 2025 · 0 citations · open access
EPIDERMOLYSIS BULLOSA HEREDITARIA: A DERMATOLOGIST‘S PERSPECTIVE AND NEWLY TREATMENT APPROACHES
AbstractIzvleekDedna bulozna epidermoliza je genetsko povzroena bolezen krhkosti koe.Doslej so bile identificirane mutacije, ki vkljuujejo vsaj 20 razlinih genov s posledino konformacijsko spremenjenostjo ali odsotnostjo beljakovin citoskeleta, celinega matriksa ali beljakovin medceline adhezije v koi.Na osnovi genetsko povzroenih molekularnih nepravilnosti in zato nastalih razslojevanj konega tkiva razlikujemo 4 osnovne tipe bolezni: simpleks, junkcijsko in distrofino dedno bulozno epidermolizo ter Kindlerjev sindrom; v sklopu osnovnih tipov poznamo vsaj 30 klinino razlinih podtipov bolezni.Pri tejih oblikah dednih buloznih epidermoliz se lahko pojavljajo zapleti na koi, sluznicah ali konih adne-
Dermatology and Dermatitis · 2020 · 0 citations · open access
Hereditary Epidermolysis Bullosa: New Description
AbstractEpidermolysis bullosa (EB) is a heterogeneous group of genetically determined, mechano-bullous disorders characterized by blister formation in response to mechanical trauma. The blistering of the skin occurs in the varying degrees of severity and can severely incapacitate the life of the afflicted patient. Epidermolysis Bullosa Simplex (EBS), the most commonly occurring type, is dominantly inherited where treatment still remains a major challenge.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
